ONCR News and Press, Oncorus Inc. From 11/30/22

Company now focused on the development of ONCR-021, Oncorus’ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023 Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being d...

ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will part...

ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical entry receptor for HSV-1, NECTIN-1, is only minimally expressed in human GBM tumors. ...

Oncorus press release ( NASDAQ: ONCR ): Q3 GAAP EPS of -$0.76. The company ended the quarter with $81.5 million in cash and cash equivalents to support next-generation viral immunotherapy pipeline. The viral immunotherapies company said it is on track to submit IN...

Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in the fourth quarter of 2022 On track to submit IND for ONCR-021 in mid-2023 Completed construction phase of GMP-compliant manufacturing facility in Andover, MA Ended ...

ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on stimulating the immune system to transform outcomes for cancer patients, today announced the publication of preclinical data in Nature Communications highlighting t...

ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will par...

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will p...

Oncorus press release ( NASDAQ: ONCR ): Q2 GAAP EPS of -$0.74 misses by $0.02 . Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022 Company remains on track to submit IND for ONCR-021 i...

Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022 Company remains on track to submit IND for ONCR-021 in mid-2023 Ended quarter with $100.2 million in cash and cash equivalents to support next-genera...